A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels

Eligibility Criteria

• * Participants with plasminogen level (concentration) within normal range at the Screening Visit.
• * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
• * Females of non-childbearing potential must be confirmed at the Screening Visit.
• * Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods from the time of first administration of study intervention until 3 months after the study Follow-up Visit.
• * Have a body mass index (BMI) between 18 and 35 kg/m2 inclusive.
• * For Japanese and Chinese participants (Parts A and B):
• 1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan.
• 2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.
• * For Part B (Global MAD Cohorts), at the Screening Visit participants must have elevated Lp(a) ≥ 30 mg/dL.
• * History of any clinically important disease or disorder.
• * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• * Participants with known bleeding or coagulation disorders.
• * Participants who have an elevated high-sensitivity C-reactive protein (\> 3 mg/L) or have a prothrombin time/international normalized ratio (PT/INR) or activated partial thromboplastin time (aPTT) \> 1.25 times × upper limit normal (ULN).
• * Any clinically important abnormalities in hematology, coagulation, clinical chemistry, urinalysis, abnormal vital signs or abnormal laboratory values.
• * Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or human immunodeficiency virus (HIV).
• * Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) at Screening.
• * Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.